Deloitte and Sanofi recently announced their collaboration on a new artificial intelligence-based software-as-a-service adverse-events case-intake platform. Dubbed ConvergeHEALTH Safety, the platform will modernize pharmacovigilance (PV) and take on some of the healthcare space’s greatest operational safety challenges.
"Reporting patient adverse events related to products or services is a critical component of Sanofi's commitment to patient safety as well as a highly regulated process with stringent compliance policies," said Stephen Kuske, Sanofi's Global Head of Pharmacovigilance Operations. "For many companies, including Sanofi, the process also involves a significant manual workload to capture, enter and report safety information to various regulatory agencies globally. By working with Deloitte, we've been able to, for the first time, optimize quality and efficiency simultaneously."
The platform is result of over two years of design, development, and implementation work, combining Deloitte’s ConvergeHEALTH Safety Platform with the industry expertise of Sanofi to deliver results such as improved case quality over manual data entry, significantly reduced case processing times, and ongoing improvements of data science model efficiencies.
The Deloitte ConvergeHEALTH Safety Platform itself was developed in conjunction with industry experts and Deloitte alliances like Amazon Web Services to provide cognitive case processing, aggregate and operational reporting, signal detection, evaluation and management, and safety metrics. The efforts have delivered benefits such as automated intake and processing, shifting case-processing activities to value-added review and analysis (versus traditional manual data entry and coding), faster, more efficient, and more consistent case processing, and a reduced total cost of ownership with enhanced regulatory compliance outcomes.
Sanofi is a market-leading biopharmaceutical research and development company with over 100,000 global employees providing healthcare solutions in 170 countries, and maintains 69 manufacturing sites and 21 R&D sites in 32 countries. The company has been heavily investing in AI technology in recent years to drive innovation, and, by implementing the ConvergeHEALTH Safety platform, has already seen improvements in both case quality and case processing within PV by automating the intake process, freeing up resources to increase focus on the rest of the adverse-case process as well as optimize the benefit-risk profiles of medicines under development.